Page 3 - Dr Reddy's
Dr Reddy's says it aims to triple reach to 1.5 bn patients by 2030
Under its sustainability goals for the next decade, Dr Reddy's said it is making its "products accessible and affordable for patients" and "25 per cent of new launches to be first to market by 2027"
 "Dr Reddy's says it aims to triple reach to 1.5 bn patients by 2030")
Launches, base biz expansion tonic for Dr Reddy's double-digit growth
While the company's bottom line grew 10.5% annually over the 2016-17 through 2021-22 (FY22) period, it is expected to register thrice that growth rate over next two years, observes ICICI Securities
 "Launches, base biz expansion tonic for Dr Reddy's double-digit growth")
Markets post best daily gains in three months; Sensex, Nifty soar nearly 3%
China rate cut helps improve sentiment
 "Markets post best daily gains in three months; Sensex, Nifty soar nearly 3%")
Dr Reddy's Q4 PAT falls 76% YoY on impairment costs; misses estimates
The company's board also recommended a final dividend of Rs 30 per equity share of face value of Rs. 5 each for the financial year 2021-22.
 "Dr Reddy's Q4 PAT falls 76% YoY on impairment costs; misses estimates")
Stocks to Watch: ITC, Lupin, Ruchi Soya, Manappuram Finance, JSW, Biocon
Stocks to Watch: The US markets suffered the biggest one-day sell-off in almost two years -Investors worry about inflation and its impact on earnings and prospects for monetary policy tightening
 "Stocks to Watch: ITC, Lupin, Ruchi Soya, Manappuram Finance, JSW, Biocon")
Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts
The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.
Stocks to Watch: RIL, HUL, Dr.Reddy's, PNB Housing, Future Retail, Banks
Reliance Industries is likely to be in limelight as the company is looking to take advantage of the surging diesel demand in Europe in the backdrop of Russia-Ukraine conflict.
 "Stocks to Watch: RIL, HUL, Dr.Reddy's, PNB Housing, Future Retail, Banks")
Sell-off toll! HDFC twins, HUL, Dr.Reddy's among Nifty50 stks at 52-wk lows
Apart from the 8 stocks among the Nifty50 index, a total of 26 stocks too dropped to their respective 52-week lows among the Nifty500 index.
 "Sell-off toll! HDFC twins, HUL, Dr.Reddy's among Nifty50 stks at 52-wk lows")
Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode
An official of Dr Reddy's Laboratories said they are closely monitoring the developments and ensuring the well-being of their staff in that region is the first and foremost priority
 "Russia-Ukraine crisis: Indian pharma exporters in wait and watch mode")
Binnopharm to acquire 2 anti-bacterial brands from Dr Reddy's
During the transition period, Dr Reddy's will continue to supply the product to Binnopharm Group to ensure availability in the market
 "Binnopharm to acquire 2 anti-bacterial brands from Dr Reddy's")
Stocks to Watch: DRL, Mankind, Sun Pharma, Wipro, Kalpataru, TTML, Airlines
Ambuja Cement, Nestle India and Veritas to announce December quarter results today.
Dr Reddy's to launch Molflu at Rs 35 per capsule for Covid treatment
The overall cost for a patient treated with a 5-day course of 40 capsules of the generic drug, to be sold under brand name 'Molflu', will come up to Rs 1,400
 "Dr Reddy's to launch Molflu at Rs 35 per capsule for Covid treatment")
Dr Reddy's inks pact with Citius Pharma to sell rights to anti-cancer agent
The drug firm said it has entered into a definitive agreement with Citius to sell all of its rights to E7777 and certain related assets.
 "Dr Reddy's inks pact with Citius Pharma to sell rights to anti-cancer agent")
Dr Reddy's, Natco Pharma launch generic cancer drug in Canada
Dr Reddy's Laboratories and Natco Pharma on Thursday said they have launched generic capsules used in the treatment of multiple myeloma and myelodysplastic syndrome patients in the Canadian market.
 "Dr Reddy's, Natco Pharma launch generic cancer drug in Canada")
DRL seeks a booster from Sputnik V but hurdles in scaling up remain
Even as the company investigates complaints of malpractice in the Ukraine, hurdles in scaling up the Russian vaccine remain the bigger challenge in the near term
 "DRL seeks a booster from Sputnik V but hurdles in scaling up remain")
Dr Reddy's to sell US, Canada territory rights for migraine drug to BDSI
Drug firm Dr Reddy's Laboratories on Wednesday said it has entered into a definitive agreement with BioDelivery Sciences International, Inc., to sell its US and Canada territory rights
DRL stock falls 10% after missing Q1 estimates, probe by US SEC
The stock fell 10.4 per cent to Rs 4,844.35 (hitting the lower circuit) on Tuesday after reporting lower-than-expected quarterly earnings for Q1FY22
Covid-19 pandemic: Sputnik V vaccine imports likely to improve from August
Trials on adolescents in Russia expected to end by October: DRL
 "Covid-19 pandemic: Sputnik V vaccine imports likely to improve from August")
Indian pharma industry to touch $130 bn by 2030: Dr Reddy's chairman
The Indian pharmaceutical industry is expected to grow almost by three times to about 130 billion US dollars by 2030
Sputnik V second dose shortage to delay India's full rollout: Dr Reddy's
Dr. Reddy's had received about 3 million first doses by June 1 and about 360,000 doses of the second by early this month, the company and the Indian government have said
 "Sputnik V second dose shortage to delay India's full rollout: Dr Reddy's")
